UNSPSC 51171628: Potassium phosphate

This classification denotes an electrolyte replacement agent with the molecular formula 2K.HO4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CI71S98N1Z, chemically known as potassium phosphate, monobasic (jan/nf) but generally known as potassium phosphate, which bears US NIH Compound Identifier 24506. European Medicines Agency schedules Potassium phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21612.

Potassium phosphate bears US NLM identifiers UMLS ID C0071778 and NCI Concept Code C29373. SMILES: OP(=O)(O)[O-].[K+].

UNSPSC 51171628 Potassium phosphate is a Commodity code that in practice encompasses chemical supply for municipal water and wastewater treatment operations. State and local procurement under this code centers on industrial chemicals used in water quality management, including related commodity specifications such as sodium bisulfite for pollution control facilities. The issuing bodies are primarily municipal water and wastewater utilities and cooperative purchasing alliances administering multistate chemical procurement for state and local health and environmental agencies. Recent solicitations show a focus on unit-cost competitive bidding for specified chemical commodities delivered on scheduled intervals, with standard municipal insurance and bonding requirements (General Liability $1,000,000–$2,000,000, performance bonds, and labor and material payment bonds where applicable).

Geographic activity includes Connecticut and participation through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, which coordinates chemical and pharmaceutical procurement across multiple states including Oregon. The City of Meriden, Connecticut posted IFB B027-15 on July 8, 2026 for sodium bisulfite chemical supply to its Water Pollution Control Facility, with bids due July 29, 2026; pricing is evaluated on unit-cost basis for estimated quantities with firm pricing requirements. MMCAP's RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, established multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent on administrative compliance and technical capability. Awarded vendors under the MMCAP contract were to be made available to wholesalers by May 15, 2026, with resulting agreements effective July 1, 2026.